| Clinical Guidelines & Position Statements |
Publication Date |
| NEW: CRA Position Statement on Citrate-Free Humira (PDF) |
May 2020 |
CRA Position Statement on COVID-19 and Hydroxychloroquine Supply (PDF)
– Frequently Asked Questions |
April 2020 |
| Canadian Rheumatology Association Policy on Potential Conflicts of Interest in the Guideline Development Process (PDF) |
June 2019 |
| Canadian Rheumatology Association Guidelines Handbook (PDF) |
May 2019 |
Canadian Rheumatology Association Position Statement on Biosimilars
– Frequently Asked Questions |
May 2019 |
Canadian Rheumatology Association Position Statement on Medical Cannabis Use in Rheumatic Disease
– Frequently Asked Questions |
January 2019 |
| Canadian Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus |
August 2018 |
| Canadian Position Statement on Opioid Therapy (PDF) |
November 2017 |
| Canadian Position Statement on Management of Juvenile Idiopathic Arthritis |
October 2016 |
| Canadian Position Statement on Ethical Prescribing (PDF) |
November 2015 |
| Editorial: Expanding Medical Marijuana Access in Canada (PDF) |
November 2015 |
| Canadian Review on Cannabinoid Treatments for Rheumatic Diseases |
November 2015 |
| Canadian Recommendations for the Management of Spondyloarthropathy |
April 2014 |
| Cardiovascular Risk with Diclofenac: Response to Health Canada (PDF) |
November 2014 |
| Chronic pain, Diclofenac and Cardiovascular Risk: Management Algorithm (PDF) |
June 2014 |
| Canadian Confidence with Cannabinoids in Rheumatic Diseases: A Survey of Rheumatologists (PDF) |
November 2014 |
| Canadian Recommendations for Management of RA |
August 2012 |
| Canadian Fibromyalgia Guidelines |
August 2012 |
